Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIIb booster study of Walvax SARS-CoV-2 mRNA vaccine after prior inactivated COVID-19 vaccination
ChiCTR2100053551Phase 3Recruiting
- Sponsor
- Walvax Biotechnology Co., Ltd.
- Start
- Nov 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of LVRNA021 and COVID-19 vaccine (Vero cell), inactivated in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Walvax Biotechnology Co., Ltd. Primary endpoints: Live virus neutralizing antibodies and Safety. Started Nov 2021; status: recruiting.
02
Drugs
LVRNA021COVID-19 vaccine (Vero cell), inactivated
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2100053551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053551.